Fudan experience of neoadjuvant treatment for rectal cancer
10.3760/cma.j.issn.1671-0274.2019.04.005
- VernacularTitle: 直肠癌新辅助治疗之复旦之路
- Author:
Jing ZHANG
1
;
Lijun SHEN
;
Juefeng WAN
;
Lifeng YANG
;
Ji ZHU
;
Zhen ZHANG
Author Information
1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
- Publication Type:Journal Article
- Keywords:
Rectal neoplasms;
Neoadjuvant therapy;
Chemoradiotherapy
- From:
Chinese Journal of Gastrointestinal Surgery
2019;22(4):336-341
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer. Fudan University Shanghai Cancer Center has carried out multiple series of studies to explore the optimization of the neoadjuvant therapy since 2005. On the one hand, the "addition" method refers to a higher intensity treatment at the neoadjuvant stage to obtain better tumor regression. On the other hand, the "subtraction" method reduces some unnecessary treatment from the current triad of surgery, radiotherapy and chemotherapy to improve the quality of life of patients. However, locally advanced rectal cancer is associated with great heterogeneity, and therefore, any single treatment mode will not be optimal for all. Notably, the treatment decision-making should be based on clinical presentations, imaging findings, and molecular biology to precisely stratify patients. Besides, the scheme should be dynamically adjusted according to the therapeutic response, so as to realize the dual goals of prolonging patients′ life and improving their quality of life. Meanwhile, the treatment decision-making for target population under the guidance of biomarker should be dynamically and self-adaptively adjusted based on the therapeutic effect. This approach will become the future development direction and objective for the precise medical treatment for rectal cancer.
